-
Bispecific Antibody Drug Conjugates Outlook 2024-2029 Featuring Alphamab, Amgen, AstraZeneca, Beijing Biocytogen, BiVictriX, Corellia AI, Debiopharm, Doma Bio, Genmab, Innovent, ProEn Therapeutics - ResearchAndMarkets.com
28 Mar 2025 14:13 GMT
… approaches and technology platforms through patents and licenses. This emphasis on … limited to:
Alphamab Oncology
Amgen
AstraZeneca
Beijing Biocytogen
BiVictriX Therapeutics
Corellia …
-
Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook
21 Mar 2025 19:15 GMT
… . And more.
1. AstraZeneca signs Alteogen deal worth up … drugs despite Merck-Halozyme patent drama
AstraZeneca has enlisted Alteogen and … biomarker-enriched patients.
6. AstraZeneca offers early look at … 3 trial rolls on
AstraZeneca found that a combination …
-
Just How Steep Is the Drug Patent Cliff? Ask These Pharmas
19 Mar 2025 15:18 GMT
… itself. This so-called patent thicket could theoretically push … with Boehringer Ingelheim and AstraZeneca scooping up billions of … a nearly picture-perfect patent cliff when generics immediately … it played regarding Remicade’s patent.
Pfizer, meanwhile, gambled …
-
Drugmaker AstraZeneca to acquire EsoBiotec for $1 billion
18 Mar 2025 00:22 GMT
… for cancer and autoimmune diseases.
AstraZeneca is a global biopharmaceutical company … partners to improve patient outcomes. AstraZeneca’s commitment to science and … a strong portfolio of both patented and generic drugs.
The transaction …
-
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
17 Mar 2025 18:52 GMT
AstraZeneca has signed two deals worth … requested the U.S. Patent and Trademark Office to reconsider seven Mdase … patents out of a total … Enhertu, which is partnered with AstraZeneca.
Daiichi declined to comment on …
-
Global Type 1 Diabetes Market Is Booming Worldwide 2025-2032: Zealand Pharma, AstraZeneca, Eli Lilly and Company, Adocia
17 Mar 2025 11:56 GMT
… & Lee Pharmaceuticals, Zealand Pharma, AstraZeneca, Eli Lilly and Company, Sanofi … Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
- Chapter 5: Displaying …
-
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal
17 Mar 2025 16:19 GMT
… development and regulatory milestones, AstraZeneca said in a statement. … CAR-T therapy, AstraZeneca said.
AstraZeneca intends to use the … the statement.
More broadly, AstraZeneca’s interest could help … mitigate the impact of patent expirations and drug-price …
-
Alteogen and AstraZeneca Forge $1.35 Bil. Partnership for Cancer Treatment Innovation
17 Mar 2025 13:47 GMT
… landmark technology export agreement with AstraZeneca to develop cancer therapeutics using … partnership, stating, "Partnering with AstraZeneca, a global leader in innovative … fields such as materials and patent rights to ensure stability, will …
-
Astrazeneca divulges new antibody-drug conjugates
11 Mar 2025 23:24 GMT
Immuno-oncology
Astrazeneca AB has synthesized antibody-drug … Antibody-drug conjugate Immuno-oncology Patents
-
Off Topic: Patent abuse is to blame for the price of prescription drugs
11 Mar 2025 13:15 GMT
…
The current medical patent system incentivizes hoarding intellectual … Many companies, like AstraZeneca, add secondary patents to the original, … to prevent patent abuse. The Patent Thickets Act … to the United States Patent and Trademark Office, which gives …